In a type-1 diabetic model, subcutaneous administration of 0.78 mg/kg/day of apigenin (4) for 10 days attenuated nephropathy features in rats by decreasing the overexpression of dynamin-related protein 1 (Drp1) in kidney tissues [184]. Here, DNM1L is linked to kidney disorder.